Provided by Tiger Trade Technology Pte. Ltd.

Merck

142.79
+0.85000.60%
Post-market: 142.820.0300+0.02%19:55 EDT
Volume:6.35M
Turnover:907.65M
Market Cap:352.29B
PE:112.18
High:144.15
Open:142.03
Low:141.49
Close:141.94
52wk High:156.92
52wk Low:82.01
Shares:2.47B
Float Shares:2.47B
Volume Ratio:0.70
T/O Rate:0.26%
Dividend:3.32
Dividend Rate:2.33%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.40
PE(LYR):19.61

Loading ...

Merck Shares Flat in Volume Spike After FDA Approves Kidney Drug, Last up 0.50% at $148.81

THOMSON REUTERS
·
Sep 25

FDA Approves Belzutifan in Combination with Lenvatinib for Advanced Renal Cell Carcinoma with a Clear Cell Component

THOMSON REUTERS
·
Sep 25

Merck Has Two Overlooked Pipeline Catalysts Coming Before Year-End, UBS Says

MT Newswires Live
·
Sep 25

Pharmaceutical Stocks Jump. Moderna, Eli Lilly up over 3%; Novavax, Pfizer up Around 2%; Merck, Novo Nordisk up over 1%

Tiger Newspress
·
Sep 24

Merck's Drug for Diabetes-Related Eye Disease Meets Trial Goal

Reuters
·
Sep 24

Merck Says Remigromig Meets Primary Endpoint in Pivotal Brunello Trial for Diabetic Macular Edema

Reuters
·
Sep 24

Merck & Co - Higher Rates of Pdr, Vitreous Hemorrhage, and Discontinuations with Remigromig

THOMSON REUTERS
·
Sep 24

Merck’s Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2B/3 Brunello Study of Adults with Diabetic Macular Edema

THOMSON REUTERS
·
Sep 24

Merck & Co Inc: Both Doses of Remigromig were Generally Well Tolerated

THOMSON REUTERS
·
Sep 24

Merck & Co - Both Remigromig Doses Show Non-Inferiority to Ranibizumab at 52 Weeks

THOMSON REUTERS
·
Sep 24

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Sep 24

TD Cowen Adjusts Merck Price Target to $155 From $137, Maintains Hold Rating

MT Newswires Live
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Celldex (CLDX) and Inventiva (IVA)

TIPRANKS
·
Sep 23

Merck & Co Inc : TD Cowen Raises Target Price to $155 from $137

THOMSON REUTERS
·
Sep 23

Wall Street Analysts Are Neutral on Top Healthcare Picks

TIPRANKS
·
Sep 23

Merck Gets FDA Label Update for WINREVAIR Based on HYPERION Trial

MT Newswires Live
·
Sep 22

Merck says FDA approves update for U.S. product label for Winrevair

TIPRANKS
·
Sep 22

U.S. FDA Approves Update to the Label for Winrevair to Include Data from the Phase 3 Hyperion Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension

Reuters
·
Sep 22

Merck Says Phase 3 Hyperion Trial Shows Winrevair Cuts PAH Clinical Worsening Risk 76%

Reuters
·
Sep 22

Nvidia Corp., Merck Share Gains Lead Dow's 425-Point Climb

Dow Jones
·
Sep 22